Key result
Targeted DTPA nanoparticles cut aortic valve calcium ~83% vs. control without affecting cellular viability.
Why the study?
Calcified aortic valve disease leads to aortic valve stenosis, but surgical intervention remains the only treatment option.
Does DTPA-coupled anti-elastin-targeted nanoparticles reverse calcification in ex vivo porcine aortic valves?
Does DTPA-coupled anti-elastin-targeted nanoparticles reverse calcification in ex vivo porcine aortic valves?
Absolute Event Rate: 0.9% vs 5.16%
p-value: p=≤0.001
Targeted delivery of the chelating agent DTPA using anti-elastin conjugated nanoparticles successfully reverses aortic valve calcification ex vivo without inducing cellular toxicity, representing a promising foundational step for pharmacological treatment of calcific aortic valve disease.
Supports targeted chelation for aortic valve calcification reversal in ex vivo models; leaves open clinical translation and in vivo efficacy.
Calcified aortic valve disease in its final stage leads to aortic valve stenosis, limiting cardiac function. To date, surgical intervention is the only option for treating calcific aortic valve stenosis. This study combined controlled drug delivery by nanoparticles (NPs) and active targeting by antibody conjugation. The chelating agent diethylenetriaminepentaacetic acid (DTPA) was covalently bound to human serum albumin (HSA)-based NP, and the NP surface was modified using conjugating antibodies (anti-elastin or isotype IgG control). Calcification was induced ex vivo in porcine aortic valves by preincubation in an osteogenic medium containing 2.5 mM sodium phosphate for five days. Valve calcifications mainly consisted of basic calcium phosphate crystals. Calcifications were effectively resolved by adding 1-5 mg DTPA/mL medium. Incubation with pure DTPA, however, was associated with a loss of cellular viability. Reversal of calcifications was also achieved with DTPA-coupled anti-elastin-targeted NPs containing 1 mg DTPA equivalent. The addition of these NPs to the conditioned media resulted in significant regression of the valve calcifications compared to that in the IgG-NP control without affecting cellular viability. These results represent a step further toward the development of targeted nanoparticular formulations to dissolve aortic valve calcifications.
No takes yet. Share an insight, caveat, or question.
Feldmann et al. (2023) studied Calcific aortic valve disease (ex vivo model). DTPA-coupled anti-elastin-targeted nanoparticles vs. Osteogenic medium control or isotype IgG-NPs was evaluated on Calcium content (μg Ca2+/mg dry weight) (p=≤0.001). Treatment with DTPA-coupled anti-elastin-targeted nanoparticles significantly reduced aortic valve calcium content to 0.90 μg/mg dry weight compared to 5.16 μg/mg in the osteogenic medium control without affecting cellular viability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: